Greenwich LifeSciences (GLSI) announced the activation of clinical sites in France. The Company has partnered with Unicancer and its breast cancer group. The FLAMINGO-01 study will be activated in approximately 19 French sites in the UCBG network. These sites were approved by French authorities in Q1 2024, which led to site initiation visits and training of 15 sites in Q2-Q4 of 2024, with the remaining 4 sites scheduled for start-up activities in Q1-Q2 of 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLSI: